Side effects of Pokr Tablet

How to use Pokr Tablet

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. It can be taken with or without food, but it is better to take Pokr 15mg Tablet at a fixed time.

How Pokr Tablet works

Pokr 15mg tablet is an anti-diabetic medication. It works by increasing the body's sensitivity to insulin, a natural substance that helps control blood sugar levels.

Notify your doctor if you experience shortness of breath, heart problems, or any abnormal swelling.

May not be suitable for patients with a history of heart failure or bladder cancer.

You should continue to exercise regularly, eat a healthy diet, and take your other diabetes medicines along with Pokr.

Warnings

Special precautions for Pokr 15mg Tablet

Alcohol

CAUTION

Taking pioglitazone with alcohol may affect blood glucose levels in patients with diabetes.

Pregnancy

WEIGH RISKS VS BENEFITS

Pokr 15mg Tablet may be unsafe to use during pregnancy.

Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor.

...

+more

Lactation

Pokr 15mg Tablet is probably safe to use during lactation.
Limited human data suggests that the drug does not represent a significant risk to the baby.

Frequently asked questions for Pokr 15mg Tablet

Frequently asked questions for Pioglitazone

No. Pokr is an anti-diabetic medication. Blood thinners are the medicine that prevents the formation of a harmful blood clot. These include medicines like Aspirin, Heparin and Warfarin.

Q. Is Pokr a diuretic?

No. Pokr is not a diuretic. It is used in the treatment of Diabetes Mellitus. Diuretics are those medicine which increases urination.

Q. Can Pokr used in Hepatitis B infection?

Some studies have shown that Pokr may be helpful in preventing Hepatitis B Virus-associated Hepatocellular Cancer (Liver Cancer). However, these findings are still very preliminary and clear role has not been established.

Pokr has been shown to inhibit Liver Cancer (HCC) recurrence in overweight Hepatitis C Virus-infected diabetic patients. It also improved insulin resistance (a state where the body is resistant to the effects and functions of the insulin hormone) in them.

Q. Can Pokr used along with Vitamin D?

Studies indicate that Vitamin-D combined with Pokr may be more effective in improving Bone Mineral Density and Bone Metabolism than Vitamin-D or Pokr alone in the treatment of Diabetes Mellitus patients with kidney dysfunction (Diabetic Nephropathy).

Q. Can Pokr be used along with sitagliptin?

Combination therapy with Sitagliptin and Pokr leads to a substantial and sustained improvement in glycemic (blood sugar) control compared to the treatment with Pokr alone. This is useful for patients who cannot tolerate Metformin or Sulfonylureas.

Recent evidence suggests that Pokr may be beneficial in Alzheimer's disease (AD), decreasing the cognitive decline early in the disease process. However, larger studies are now in progress to establish the same.

Q. Can Pokr and repaglinide combined in diabetes treatment?

For patients who previously failed oral antidiabetic therapy, the combination of Repaglinide and Pokr have acceptable safety, with greater reductions of glycemic parameters (blood sugar levels) than using either agent alone.

Large population studies indicate that Pokr is associated with an increased risk of bladder cancer. The absence of an association of bladder cancer with the other drug of the same class, Rosiglitazone, suggests that the increased risk is drug specific and not a class effect.

Q. Are Pokr and rosiglitazone same?

Pokr & Rosiglitazone both belong to a class of antidiabetics called Thiazolidinediones. Rosiglitazone has been removed from the market because using this drug was associated with increased risk of cardiovascular events like heart attack and stroke. This is not seen with Pokr.

Q. Can Pokr be used along with glimepiride in diabetes?

Pokr when added to Glimepiride in Patients with Diabetes Mellitus, has been found to significantly reduce plasma lipid levels and significant improvement in blood pressure control related to a reduction in the insulin resistance.

Pokr is an anti-diabetes drug used along with a proper diet and exercise program to control high blood sugar in patients with type 2 diabetes. Pokr acts as an insulin sensitizer and decreases the extent of insulin resistance in the body too.

Pokr increases the permeability of fluid in tiny blood vessels called capillaries. This results in easier movement of fluids across the membrane and their consequent accumulation, resulting in oedema (puffiness). Also, Pokr causes increased sodium and water reabsorption from the kidney that contributes to the oedema.

The mechanism behind the link between Pokr use and bladder cancer is still unknown. Studies have suggested that use of Pokr for more than one year results in increased risk of development of tumour of the urinary bladder.

Pokr can cause fluid retention and edema. Consequently, there is a lot of fluid in the body (fluid overload). As a result, it may precipitate heart failure (which worsens with fluid overload in those at risk).

Studies in animals have concluded that Pokr improves the elasticity of the aortic wall ( the aorta is a large blood vessel that arises from the heart and supplies oxygenated blood to the rest of the body). This may be a mechanism by which it protects against atherosclerosis, but more studies are needed to confirm this.

The addition of Pokr reduces daily insulin dosages, but study findings have not been consistent. Improvement of lipid profiles has also been weak with this combination therapy. Long-term studies are needed before any conclusions can be reached. Combination therapy should be primarily used for patients who achieve an insufficient reduction in blood sugar with insulin alone.

Q. Which is not safe in heart failure, Pokr or rosiglitazone?

Pokr & Rosiglitazone both belong to a class of antidiabetics called Thiazolidinediones. Rosiglitazone has been removed from the market because using this drug was associated with increased risk of cardiovascular events like heart attack and stroke. Pokr can cause heart failure too, but the risk is less that that with Rosiglitazone. Both the medicines should be avoided in heart failure.

Findings indicate that Pokr treatment is associated with a reduced dementia risk in Diabetes mellitus patients. Prospective studies are needed to evaluate a possible neuroprotective effect in these patients in an ageing population.

The use of Pokr for plaque psoriasis treatment is controversial. Some studies revealed no effect of Pokr 30 mg daily neither on the clinical response of moderate-to-severe psoriasis whereas others demonstrate that it could be considered as an efficacious and safe agent for the treatment of plaque psoriasis.

In a research study in a small number of autistic children, daily treatment with 30 or 60 mg Pokr for 3–4 months induced apparent clinical improvement. Pokr should be considered for further testing of therapeutic potential in autistic patients but as of now, autism is not an approved indication for Pokr use.

A recent study shows that although Pokr causes a significant decrease in blood sugar, HbA1C and lipid levels, it is associated with weight gain, which would limit its utility. It has not been shown to cause weight loss.